Merck, Pfizer’s Bavencio Misses Ovarian Cancer Trial Endpoints

November 26, 2018 7:45 pm

By Selina McKee

A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

The drug was being tested as monotherapy and in combination with … Read more

New Dual-Action Cancer-Killing Virus

November 18, 2018 8:00 pm

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

It is the first time that cancer-associated fibroblasts … Read more

Immunotherapy Has Big Potential In Ovarian Cancer Treatment

November 27, 2017 8:50 pm

Early studies are showing promise for immunotherapy agents such as checkpoint inhibitors in the treatment field of ovarian cancer, according to Jonathan Ledermann, M.D.

One such study is JAVELIN Ovarian 200, a study of Bavencio (avelumab) alone or in combination … Read more

What Is Immunotherapy? The Basics on These Cancer Treatments

August 23, 2017 2:55 pm

Some of the most promising advances in cancer research in recent years involve treatments known as immunotherapy. These advances are spurring billions of dollars in investment by drug companies, and are leading to hundreds of clinical trials. Here are answers … Read more

Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer

March 24, 2017 4:29 am

The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, specifically in patients who … Read more

Combination Of Chemotherapy And Immunotherapy May Be Effective

June 8, 2016 7:04 pm

Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles: The bad cells are fibroblasts. They work to block chemotherapy, which is why nearly every woman with ovarian cancer becomes resistant to treatment. … Read more